Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

133
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
133
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

211
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
211
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

303
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
303
Pneumonia IV: Management01:28

Pneumonia IV: Management

299
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
299

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in China.

Annals of clinical microbiology and antimicrobials·2026
Same author

Transformative Powder Fibration toward Hierarchical Ceramic Aerogels for Multifunctional Aerospace Systems.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Bio-Inspired Topologically Constrained, Interlocking-like Cellulose Architectures via Sacrificial Oligomer Templating.

ACS applied materials & interfaces·2026
Same author

The α1 subunit-containing GABA<sub>A</sub> receptor-mediated inhibitory transmission in the lateral orbitofrontal cortex contributes to anxiety- and depression-like behaviors in Parkinsonian rats.

Neuropharmacology·2026
Same author

A multi-center clinical evaluation on first-in-class ROP-based IGRA for tuberculosis diagnosis.

iScience·2026
Same author

SYTL2 and DENND2B as shared drivers in mouse abdominal aortic aneurysm and lung cancer.

iScience·2026

Related Experiment Video

Updated: Jun 5, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K

Therapeutic Strategies for Tuberculosis: Progress and Lessons Learned.

Qingfeng Sun1, Shanshan Li2, Mengqiu Gao3

  • 1Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China;The Second Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.

Biomedical and Environmental Sciences : BES
|December 12, 2024
PubMed
Summary

Tuberculosis treatment faces challenges from drug-resistant strains. New drugs, regimens like BPaLM, and immunotherapy offer hope for reducing the global TB burden.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K
A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

187

Related Experiment Videos

Last Updated: Jun 5, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K
A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

187

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Immunology

Background:

  • Tuberculosis (TB) is a leading infectious cause of death, with drug resistance (RR-TB, MDR-TB, XDR-TB) compromising treatment efficacy.
  • First-line TB drugs are less effective against resistant strains, necessitating more toxic and less accessible second-line options.

Purpose of the Study:

  • To review recent advances in tuberculosis therapeutics.
  • To highlight novel drug candidates, innovative treatment regimens, and emerging immunotherapies for TB.
  • To discuss challenges and future directions in combating the global TB epidemic.

Main Methods:

  • Review of current literature on tuberculosis treatment advancements.
  • Analysis of novel drug compounds, combination therapies (e.g., BPaLM protocol), and immunomodulatory agents.
  • Exploration of personalized medicine approaches and cell-based therapies.

Main Results:

  • Several new agents (e.g., bedaquiline analogs, delamanid, pretomanid) show promise against resistant Mycobacterium tuberculosis strains.
  • Innovative regimens like BPaLM offer shorter, all-oral treatment with higher cure rates.
  • Immunotherapies and cell therapies are emerging as complementary strategies.

Conclusions:

  • Despite progress, significant challenges persist in achieving global TB elimination goals.
  • Novel therapeutic strategies, optimized regimens, and continued research are crucial.
  • Global collaboration is essential to reduce the worldwide burden of tuberculosis.